Tubize-Fin Market Cap ($7.82 Billion)
Market Cap & Net Worth: Tubize-Fin (TUB)
Tubize-Fin market cap. Tubize-Fin (BR:TUB) has a market capitalization of $7.82 Billion (€6.69 Billion) as of November 1, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #2560 globally and #13 in its home market, demonstrating a 9.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tubize-Fin's stock price €229.80 by its total outstanding shares 44512598 (44.51 Million). Also see TUB cash generation efficiency for how efficiently the company converts equity into cash flow.
Tubize-Fin Market Cap History (2015–2026)
Tubize-Fin market cap history from 2015 to 2026. Data shows growth from $3.34 Billion to $11.96 Billion (13.79% CAGR). Check TUB stock price for real-time trading data and today's change.
Index Memberships
Tubize-Fin is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$835.48 Billion | 0.94% | #18 of 108 |
Weight: Tubize-Fin's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tubize-Fin Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tubize-Fin's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Tubize-Fin equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
558201.29x
Tubize-Fin's market cap is 558201.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
82.13x
Tubize-Fin's market cap is 82.13 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.93 Billion | $302.00K | $181.19 Million | 9711.85x | 16.19x |
| 2017 | $3.18 Billion | $272.23 Million | $285.93 Million | 11.66x | 11.11x |
| 2018 | $3.04 Billion | $288.25 Million | $285.16 Million | 10.53x | 10.65x |
| 2019 | $3.20 Billion | $3.00K | $283.70 Million | 1065652.36x | 11.27x |
| 2022 | $3.63 Billion | $8.15K | $85.17 Million | 445300.95x | 42.62x |
| 2024 | $7.40 Billion | $13.26K | $90.10 Million | 558201.29x | 82.13x |
Competitor Companies of TUB by Market Capitalization
Companies near Tubize-Fin in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Tubize-Fin for a full breakdown of the balance sheet.
Key companies related to Tubize-Fin by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Tubize-Fin (2015–2026)
Market capitalization of Tubize-Fin from 2015 to today. Between 2015 and today, Tubize-Fin's market cap moved from $3.34 Billion to $ 11.96 Billion, with a yearly change of 13.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.96 Billion | +9.95% |
| 2025 | €10.88 Billion | +46.98% |
| 2024 | €7.40 Billion | +99.73% |
| 2023 | €3.70 Billion | +2.08% |
| 2022 | €3.63 Billion | -21.14% |
| 2021 | €4.60 Billion | +9.96% |
| 2020 | €4.19 Billion | +30.93% |
| 2019 | €3.20 Billion | +5.29% |
| 2018 | €3.04 Billion | -4.38% |
| 2017 | €3.18 Billion | +8.27% |
| 2016 | €2.93 Billion | -12.21% |
| 2015 | €3.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Tubize-Fin was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.82 Billion USD |
| MoneyControl | $7.82 Billion USD |
| MarketWatch | $7.82 Billion USD |
| marketcap.company | $7.82 Billion USD |
| Reuters | $7.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.